Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients.Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity.The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused on the lungs, pancreas, and liver.